Search
Editas Medicine Inc
EDITAdd to Watchlist
2.580USD
-0.110-4.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
432.90MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Editas Medicine Inc is 7.17, ranking 308 out of 385 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 13.00 and a low of 1.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
5.660
Target Price
+119.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Editas Medicine Inc
EDIT
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Editas Medicine Inc's expected revenue for the next quarter?
Editas Medicine Inc's expected revenue is 2.80M.
What is Editas Medicine Inc's price target?
Analysts forecast that Editas Medicine Inc's price target is USD 4.00, with the highest forecast at USD 13.00 and the lowest forecast at USD 1.00.
How have Editas Medicine IncEDIT's recent earnings per share performed?
The market expectation was USD -0.26, while Editas Medicine IncEDIT's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.27.
What is the analyst rating for Editas Medicine Inc?
Based on the ratings of Editas Medicine Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.